Product verification: This description assumes Taficita 200 mg/25 mg contains emtricitabine 200 mg and tenofovir alafenamide 25 mg. Confirm both ingredients, their strengths, the manufacturer, and the product’s approved indications from its packaging and local prescribing information.
Important Safety Warning: Taficita contains two antiretroviral medicines. It is not a complete HIV treatment regimen when used alone. For HIV treatment, it must be combined with other appropriate antiretroviral medicines. In jurisdictions where this combination is approved for HIV prevention, it may be prescribed as pre-exposure prophylaxis (PrEP) only after confirming HIV-negative status and meeting other eligibility requirements.
People with hepatitis B virus (HBV) infection may experience serious hepatitis flare-ups after discontinuing emtricitabine/tenofovir alafenamide. Medical monitoring is essential.
What Is Taficita 200 mg/25 mg?
Taficita 200 mg/25 mg is a fixed-dose combination antiretroviral medicine containing emtricitabine and tenofovir alafenamide.
Both ingredients belong to the nucleoside/nucleotide reverse transcriptase inhibitor class.
They work by interfering with the HIV reverse transcriptase enzyme, which the virus needs to reproduce.
By inhibiting viral replication, these medicines help reduce the amount of HIV in the body when used as part of an effective combination antiretroviral treatment regimen.
Emtricitabine and tenofovir alafenamide are commonly used as the two-drug NRTI backbone of several HIV treatment regimens.
The same ingredient combination is also used for HIV pre-exposure prophylaxis in certain countries and populations, subject to regulatory approval and eligibility requirements.
Important: Taficita does not cure HIV infection. Effective treatment can suppress HIV replication and help maintain immune health, but ongoing medical care remains necessary.
How Does Taficita 200 mg/25 mg Work?
1. Combines Two Antiretroviral Ingredients
Taficita contains emtricitabine and tenofovir alafenamide, which target HIV replication through related mechanisms.
2. Inhibits HIV Reverse Transcriptase
HIV uses reverse transcriptase to convert its RNA into DNA during its replication cycle.
3. Emtricitabine Interferes With Viral DNA Synthesis
Emtricitabine is converted inside cells into its active phosphorylated form.
This active form competes with natural nucleotides and interrupts viral DNA synthesis.
4. Tenofovir Alafenamide Delivers Tenofovir
Tenofovir alafenamide is a prodrug that is converted inside cells to tenofovir and subsequently to its active form, tenofovir diphosphate.
5. Prevents Viral DNA Chain Extension
The active metabolites interfere with viral DNA synthesis and cause chain termination.
6. Reduces HIV Replication
When used with an appropriate complete HIV regimen, the combination helps suppress viral multiplication.
7. Supports Immune System Health
Sustained viral suppression can help preserve or restore CD4 T-cell counts and reduce HIV-related complications.
8. Provides a Foundation for Combination Therapy
Emtricitabine and tenofovir alafenamide are frequently paired with a third antiretroviral agent or other suitable medicines to form a complete HIV treatment regimen.
Important: These medicines do not eliminate latent HIV reservoirs and therefore do not cure HIV.
Uses of Taficita 200 mg/25 mg
1. HIV-1 Infection Treatment
Taficita may be used as part of a complete antiretroviral regimen for HIV-1 infection.
It must be combined with other appropriate antiretroviral medicines according to the prescribed treatment plan.
2. HIV Viral Load Suppression
The combination helps reduce HIV replication when used with an effective treatment regimen.
3. Supporting CD4 Cell Recovery
Effective antiretroviral treatment may help improve or preserve immune function.
4. Reducing HIV-Related Complications
Sustained HIV suppression reduces the risk of opportunistic infections and other HIV-related illnesses.
5. Long-Term HIV Management
The ingredients may form part of long-term antiretroviral therapy under specialist supervision.
6. Combination Antiretroviral Treatment
Emtricitabine and tenofovir alafenamide are commonly used with other antiretroviral agents.
7. HIV-1 Pre-Exposure Prophylaxis (PrEP)
In certain jurisdictions, emtricitabine 200 mg/tenofovir alafenamide 25 mg is approved for HIV-1 PrEP in eligible HIV-negative individuals.
However, this combination is not approved for HIV prevention in people at risk through receptive vaginal sex under the US reference labeling, because effectiveness for that exposure route has not been established.
Taficita’s own PrEP authorization must be verified locally.
8. Reducing the Risk of HIV Transmission During Treatment
When a person with HIV maintains a confirmed, sustained undetectable viral load through effective treatment, they do not sexually transmit HIV (Undetectable = Untransmittable, or U=U).
This benefit depends on sustained viral suppression, not on taking Taficita alone.
9. Maintaining Viral Suppression
The combination may be included in an appropriate regimen for patients who have achieved viral suppression.
10. Individualized Antiretroviral Therapy
A healthcare professional may select this combination based on treatment history, resistance testing, kidney function, hepatitis B status, and other clinical considerations.
Important: Taficita should not be promoted as a complete HIV treatment, a cure for HIV, or a universal HIV prevention medicine.
Taficita 200 mg/25 mg Dosage and Administration
The prescribed regimen depends on whether the medicine is being used for HIV treatment or an approved HIV prevention indication.
General Dosage Information
| Dosage Information | Details |
|---|---|
| Tablet Strength | Emtricitabine 200 mg + Tenofovir Alafenamide 25 mg |
| Common Adult Frequency | One tablet once daily for the reference fixed-dose combination |
| Administration Route | Oral |
| HIV Treatment | Must be combined with other appropriate antiretroviral medicines |
| PrEP | Only when approved and the patient meets eligibility requirements |
| Food Instructions | Reference combination may be taken with or without food |
| Treatment Duration | Determined by the indication and healthcare professional |
| Kidney Function | Requires assessment before and during treatment |
| Hepatitis B Status | Must be assessed because discontinuation may trigger hepatitis flare-ups |
| Medical Supervision | Required |
Important: The dosage above reflects commonly used reference prescribing information for emtricitabine/tenofovir alafenamide 200 mg/25 mg. The exact Taficita label and patient-specific instructions take precedence.
General Administration Instructions
- Take Taficita exactly as prescribed.
- Swallow the tablet whole with water.
- Take it at approximately the same time each day.
- Do not change the prescribed dose independently.
- Do not discontinue treatment without medical advice.
- If treating HIV, take the other prescribed antiretroviral medicines.
- Attend scheduled viral load and laboratory monitoring appointments.
- Inform the healthcare professional about all other medicines and supplements.
- Follow HIV testing requirements if prescribed for PrEP.
- Report significant side effects promptly.
- Inform the prescriber about hepatitis B infection.
- Maintain consistent treatment adherence.
Can Taficita Be Taken With Food?
The reference emtricitabine/tenofovir alafenamide 200 mg/25 mg combination may generally be taken with or without food.
Follow the product-specific instructions.
What If a Dose Is Missed?
Take the missed dose when remembered unless it is nearly time for the next scheduled dose.
Do not double the dose.
Contact the prescribing healthcare professional if multiple doses are missed or if there is uncertainty about the schedule.
Can Taficita Be Stopped Suddenly?
Do not discontinue Taficita without medical advice.
Stopping antiretroviral therapy may allow HIV viral load to increase.
Patients with hepatitis B infection may also experience serious hepatitis flare-ups after discontinuation.
Is Taficita a Complete HIV Treatment?
No.
Emtricitabine and tenofovir alafenamide are generally used with additional antiretroviral agents for HIV treatment.
Taking only these two ingredients to treat established HIV may result in inadequate viral suppression and drug resistance.
How Long Does Taficita Take to Work?
The active ingredients begin interfering with HIV replication after administration.
However, the time required to achieve viral suppression depends on the complete treatment regimen, baseline viral load, resistance profile, adherence, and individual response.
With effective combination antiretroviral therapy, HIV viral load commonly declines over the first several weeks.
Many patients achieve viral suppression within several months, although the timeline varies.
Healthcare professionals assess treatment effectiveness through HIV viral load testing rather than symptoms alone.
For PrEP, protection depends on the exposure route, adherence, and time taken to achieve protective drug concentrations. Patients should not assume immediate protection after the first dose.
Common Side Effects
Possible side effects include:
- Headache
- Nausea
- Diarrhea
- Fatigue
- Abdominal discomfort
- Mild gastrointestinal disturbances
Not every patient experiences these effects.
Side effects may also arise from other medicines used in the complete antiretroviral regimen.
Potentially Harmful Effects & Serious Health Risks
1. Hepatitis B Flare-Ups After Discontinuation
Patients with hepatitis B infection may develop severe worsening of hepatitis after stopping emtricitabine/tenofovir alafenamide.
2. Kidney Problems
Although tenofovir alafenamide generally has a more favorable renal safety profile than tenofovir disoproxil fumarate in comparative studies, kidney injury can still occur.
3. Fanconi Syndrome
Rare cases of proximal renal tubulopathy, including Fanconi syndrome, have been reported with tenofovir-containing medicines.
4. Lactic Acidosis
Rare but serious lactic acidosis has been associated with nucleoside/nucleotide analogue medicines.
5. Severe Liver Problems
Serious hepatomegaly with steatosis and other liver-related complications have been reported with medicines in this class.
6. Drug Resistance
Inadequate HIV treatment or use of PrEP during undiagnosed HIV infection may contribute to antiretroviral resistance.
7. HIV Infection During PrEP
PrEP substantially reduces HIV risk when used correctly but does not provide complete protection.
8. Reduced Effectiveness From Drug Interactions
Certain medicines may lower tenofovir alafenamide concentrations and reduce effectiveness.
9. Bone Health Concerns
Tenofovir alafenamide generally has less impact on bone mineral density than tenofovir disoproxil fumarate, but bone-related risks may still require assessment.
10. Immune Reconstitution Inflammatory Syndrome
Patients starting effective HIV treatment may develop inflammatory reactions to previously unrecognized or residual infections.
11. Severe Allergic Reactions
Hypersensitivity reactions may occur.
12. Treatment Failure
Poor adherence, drug interactions, or resistance may lead to inadequate viral suppression.
Emergency warning: Seek urgent medical attention for severe weakness, unusual breathing difficulties, persistent vomiting, significant abdominal pain, jaundice, markedly reduced urination, or symptoms suggesting serious liver or kidney injury.
Contraindications & Safety Precautions
1. Allergy to Active Ingredients
Do not take Taficita if allergic to emtricitabine, tenofovir alafenamide, or another formulation ingredient.
2. HIV Status Before PrEP
Patients must have confirmed HIV-negative status before starting PrEP.
Testing must also be repeated at recommended intervals during PrEP.
3. Acute HIV Infection
Starting PrEP during undiagnosed acute HIV infection may lead to drug resistance.
Symptoms of recent HIV infection should prompt appropriate testing.
4. Hepatitis B Infection
Patients should be assessed for hepatitis B before treatment because stopping the medicine may cause hepatitis flare-ups.
5. Kidney Disease
Kidney function should be assessed before treatment and monitored when clinically indicated.
6. Severe Renal Impairment
The reference emtricitabine/tenofovir alafenamide combination is generally not recommended for certain patients with creatinine clearance below 30 mL/min, with specific exceptions and restrictions depending on indication and dialysis status.
7. Liver Disease
Patients with liver disease require appropriate clinical assessment.
8. Pregnancy
Use during pregnancy requires individualized evaluation of maternal health, HIV treatment needs, and fetal safety.
9. Breastfeeding
Breastfeeding recommendations depend on HIV status, treatment indication, local guidance, and individual circumstances.
Patients should discuss this with their HIV specialist.
10. Children and Adolescents
Eligibility depends on age, body weight, indication, and local product approval.
11. Older Adults
Older adults may require additional kidney function monitoring and medication review.
12. HIV Drug Resistance
Resistance testing may influence treatment selection for patients with established HIV infection.
13. Adherence
Consistent dosing is essential for effective HIV treatment and PrEP.
14. Sexually Transmitted Infections
PrEP does not protect against other sexually transmitted infections such as syphilis, gonorrhea, or chlamydia.
15. Drug Interactions
Potentially important interactions include:
- Rifampicin: May significantly reduce tenofovir alafenamide exposure.
- Rifabutin and Rifapentine: May reduce tenofovir alafenamide concentrations.
- Carbamazepine: May reduce tenofovir alafenamide exposure.
- Phenytoin: May reduce tenofovir alafenamide exposure.
- Phenobarbital: May reduce tenofovir alafenamide exposure.
- Oxcarbazepine: May reduce tenofovir alafenamide exposure.
- St. John’s Wort: May reduce tenofovir alafenamide concentrations.
- Certain Antiviral Medicines: May cause overlapping toxicity or duplicate therapy.
- Nephrotoxic Medicines: May increase kidney-related risks.
16. Duplicate Antiretroviral Ingredients
Patients should not combine Taficita with other medicines containing the same ingredients unless specifically directed by a specialist.
17. Medical Monitoring
Healthcare professionals may monitor:
- HIV viral load
- CD4 cell count when indicated
- Kidney function
- Serum creatinine
- Estimated creatinine clearance
- Urine glucose and protein when indicated
- Hepatitis B status
- Liver function
- HIV resistance profile
- Medication adherence
- Drug interactions
- Pregnancy status when relevant
- Bone health when clinically indicated
- HIV testing during PrEP
- Sexually transmitted infection screening during PrEP
Advantages
- Combines two established antiretroviral ingredients.
- Once-daily administration in standard reference regimens.
- Oral tablet formulation.
- Supports effective combination HIV treatment.
- Inhibits HIV reverse transcriptase.
- May help reduce HIV viral load as part of complete therapy.
- Supports long-term HIV management.
- Used as an NRTI backbone in several regimens.
- Tenofovir alafenamide generally has a more favorable renal and bone safety profile than tenofovir disoproxil fumarate.
- May be used for PrEP in approved populations and jurisdictions.
- Fixed-dose combination reduces the number of separate tablets required for these two ingredients.
Disadvantages / Limitations
- Not a complete HIV treatment regimen when used alone.
- Does not cure HIV.
- Requires consistent adherence.
- May cause nausea.
- May cause headache.
- May cause diarrhea.
- May cause fatigue.
- May cause kidney-related adverse effects.
- Rarely associated with lactic acidosis.
- Requires hepatitis B assessment.
- Stopping treatment may cause hepatitis B flare-ups.
- May interact with certain medicines.
- Requires regular medical monitoring.
- PrEP requires confirmed HIV-negative status.
- PrEP does not prevent other sexually transmitted infections.
- Not suitable for all HIV exposure routes under certain regulatory approvals.
- May contribute to resistance if used inappropriately.
- Requires caution in significant kidney impairment.
- Pregnancy and breastfeeding require individualized assessment.
- Product-specific approvals vary by country.
Important Notes
Brand Name: Taficita.
Generic Name: Emtricitabine + Tenofovir Alafenamide.
Strength: 200 mg/25 mg.
Drug Class: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
Therapeutic Category: Antiretroviral / HIV Medicine.
Primary Use: HIV-1 treatment as part of a complete regimen.
Additional Use: HIV-1 PrEP where approved and appropriate.
Mechanism: Inhibition of HIV reverse transcriptase.
Administration Route: Oral.
Common Reference Frequency: Once daily.
Major Warning: Hepatitis B flare-ups after discontinuation, kidney toxicity, lactic acidosis, and potential drug resistance.
HIV Treatment Warning: Must be combined with other appropriate antiretroviral medicines.
PrEP Warning: Confirm HIV-negative status before starting and during treatment.
Pregnancy Warning: Requires individualized medical assessment.
Prescription Status: Prescription Medicine.
Storage: Follow manufacturer instructions.
Frequently Asked Questions
1. What is Taficita 200 mg/25 mg used for?
Taficita contains emtricitabine and tenofovir alafenamide. This combination is used as part of complete HIV-1 treatment regimens and may be used for PrEP where specifically approved.
2. What are the active ingredients in Taficita?
The stated ingredients are emtricitabine 200 mg and tenofovir alafenamide 25 mg.
3. Is Taficita an HIV medicine?
Yes. It contains two antiretroviral ingredients that inhibit HIV reverse transcriptase.
4. Can Taficita cure HIV?
No. It can help suppress HIV replication as part of effective treatment, but it does not cure HIV.
5. Is Taficita a complete HIV treatment?
No. For established HIV infection, emtricitabine/tenofovir alafenamide must be combined with other appropriate antiretroviral medicines.
6. Can Taficita be used for HIV prevention?
The ingredient combination is approved for PrEP in certain jurisdictions and eligible populations. Taficita’s specific approval must be confirmed.
7. Can Taficita prevent HIV from every type of sexual exposure?
No. Under US reference labeling, emtricitabine/tenofovir alafenamide PrEP is not approved for people at risk through receptive vaginal sex because effectiveness for that exposure route has not been established.
8. How does Taficita work?
Its active ingredients inhibit HIV reverse transcriptase, interfering with viral DNA synthesis and replication.



































































Klarissa Smith (verified owner) –
Boosted my confidence, noticeable difference!
Richard Withrow (verified owner) –
Increased pleasure, amazing stamina boost!
Deborah Carl (verified owner) –
Natural ingredients, great effects, no side effects!